Mezzelani P, Quaglio G, Venturini L, Lugoboni F
Istituto di Clinica Medica, Università, Verona.
Recenti Prog Med. 1994 Sep;85(9):419-24.
From 1985 through 1992 the following hepatitis B markers HBsAg, anti-HBs and anti-HBc were evaluated in 1797 injecting drug users (IDUs) attending 8 Centers for drug addicts in the Veneto region (north-east Italy). Among all IDUs, 1004 (56%) proved to be positive for at least one of the above markers. In particular our aim was to study the carriers of only anti-HBc. At entry, among these 1004 IDUs, 294 (29%) showed only the anti-HBc; 141 IDUs of them have been followed for a period of time: 77% remained without any marker change and 23% showed the appearance of anti-HBs. Subsequently, other 75 IDUs became carrier only of the anti HBc, for the following reasons: loss of anti-HBs (57%) or HBsAg (15%) appearance only of anti-HBc (28%). No carrier of only anti-HBc seroconverted for HBsAg. The evaluation of our data supports the hypothesis that the carrier status of the only anti-HBc prevents from reinfection by HBV and therefore these subjects do not need vaccination.
1985年至1992年期间,对意大利东北部威尼托地区8家戒毒中心的1797名注射吸毒者(IDU)进行了以下乙肝标志物检测:乙肝表面抗原(HBsAg)、乙肝表面抗体(抗-HBs)和乙肝核心抗体(抗-HBc)。在所有IDU中,1004人(56%)至少有上述一种标志物呈阳性。我们的具体目的是研究仅乙肝核心抗体阳性者。在这1004名IDU入组时,294人(29%)仅乙肝核心抗体呈阳性;其中141名IDU随访了一段时间:77%的人标志物无变化,23%的人出现了乙肝表面抗体。随后,另外75名IDU仅成为乙肝核心抗体携带者,原因如下:乙肝表面抗体消失(57%)或乙肝表面抗原出现(15%),仅乙肝核心抗体出现(28%)。没有仅乙肝核心抗体携带者发生乙肝表面抗原血清学转换。对我们数据的评估支持了以下假设:仅乙肝核心抗体携带者状态可防止再次感染乙肝病毒,因此这些受试者无需接种疫苗。